RxSight stock edges higher after insider tax sales and Q2 beat

RxSight stock is trading near 7 dollars as of early September 2026 after executives reported tax-related share sales and the company posted a smaller than expected Q2 2026 loss on double digit revenue growth.

RxSight stock (ISIN US78419L1008) is trading at about 7.03 USD as of September 2, 2026 on the NASDAQ, valuing the ophthalmic device specialist at roughly 292 million USD according to market data providers.

Insider tax transactions shape the latest headlines

On September 2, 2026, RxSight disclosed that its chief medical officer sold 5,100 common shares at a price of 6.96 USD per share, a transaction totaling 35,496 USD executed to cover tax withholding on vested restricted stock units, rather than a discretionary sale, as detailed in a filing overview reported by Stock Titan.

A separate notice summarized by Stock Titan shows that an RxSight officer plans the sale of 7,765 shares under Rule 144, with an aggregate market value of 54,044.40 USD based on the referenced share price and indicating that these shares also stem from restricted stock unit vesting on August 31, 2026.

Q2 2026 results beat expectations but guidance withdrawn

In its most recent reporting period for the second quarter of 2026, RxSight posted an adjusted loss of 0.11 USD per share, substantially better than the market consensus loss estimate of 0.36 USD per share, according to a summary of the results cited in an insider trading article on Investing.com.

The same Q2 2026 overview notes that quarterly revenue reached 33.74 million USD, exceeding the referenced projection of 32.21 million USD and underlining that RxSight grew sales by around 1.53 million USD above the cited forecast in the period.

Despite beating expectations on both revenue and earnings in Q2 2026, management withdrew its full year guidance, with market reports attributing the move to ongoing challenges in the companys core business and acknowledging that the decision triggered weakness in after hours trading when it was announced.

Analyst stance and stock performance context

A same day note compiled by MarketBeat and referenced in its RxSight coverage indicates that, based on recent analyst research, RxSight currently holds an average rating of Reduce and an average target price of 8.37 USD, suggesting modest upside potential versus the roughly 7.03 USD trading level cited for September 2, 2026 in that overview.

Insider trading write ups on Investing.com state that RxSight shares are trading at 7.03 USD with a market capitalization of about 292 to 292.4 million USD as of early September 2026, and the articles add that the stock is down around 32.5 percent year to date even though the company maintains more cash than debt on its balance sheet.

In addition, analysis modules presented alongside the insider summaries describe a fair value indication of 8.62 USD for RxSight shares, which would be around 22.6 percent above the 7.03 USD reference price, highlighting that valuation models see room for recovery despite the year to date drawdown.

Adjustable IOL system as core product

RxSight is known for its light adjustable intraocular lens system used in cataract surgery, which allows surgeons to fine tune the refractive power of the implanted lens after surgery through a series of light treatments, aiming to improve uncorrected visual acuity for patients seeking reduced dependence on glasses.

The companys commercial strategy in recent years has focused on expanding the installed base of its light delivery devices in ophthalmology practices and increasing utilization of its light adjustable lenses, and recent revenue growth in Q2 2026 suggests that adoption of these premium cataract solutions continues to contribute meaningfully to the top line.

RxSight stock at around 7 USD per share

According to recent NASDAQ trading data summarized by MarketBeat and Investing.com, RxSight stock closed at 7.03 USD on September 2, 2026, compared with insider tax driven sale prices of 6.96 USD per share on the same date, indicating that the shares are trading slightly above the level used to calculate the officers tax related transactions.

RxSight stock facts

• Company: RxSight Inc.
• ISIN: US78419L1008
• Ticker: RXST
• Trading venue: NASDAQ
• Price (as of September 2, 2026): 7.03 USD
• Market capitalization: 292,000,000 USD (as of September 2, 2026)
• Sector / Industry: Health Care / Medical Devices
• Index membership: None major